Labcorp Holdings Inc. has announced plans to offer the Elecsys pTau181 test, the first blood test cleared by the U.S. Food and Drug Administration (FDA) to help rule out Alzheimer's-related amyloid pathology in primary care settings. Developed by Roche Diagnostics, this FDA-cleared test will be made available nationwide by Labcorp by early 2026. The test, performed via a simple blood draw, provides a less invasive and more accessible alternative to traditional diagnostic methods such as lumbar punctures and PET scans for Alzheimer's disease and other causes of cognitive decline.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC05107) on October 23, 2025, and is solely responsible for the information contained therein.